ImmunityBio (IBRX) Total Liabilities (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Total Liabilities data on file, last reported at $1.5 billion in Q1 2026.

• On a quarterly basis, Total Liabilities rose 69.5% year-over-year to $1.5 billion in Q1 2026; TTM through Mar 2026 was $1.5 billion, a 69.5% increase from a year earlier, with the FY2025 full-year figure at $1.0 billion, up 14.97% from the prior year.
• Total Liabilities for Q1 2026 stood at $1.5 billion, up from $1.0 billion in the prior quarter.
• Over the last five years, Total Liabilities for IBRX reached as high as $1.5 billion in Q1 2026 and fell as low as $727.1 million in Q1 2022.
• Historically, Total Liabilities has averaged $967.3 million across 5 years, with a median of $936.4 million in 2023.
• Across the five-year window, Total Liabilities jumped 93.4% in 2022 and declined 20.11% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $812.2 million in 2022, then surged by 34.26% to $1.1 billion in 2023, then slipped by 20.11% to $871.1 million in 2024, then rose by 14.97% to $1.0 billion in 2025, then surged by 51.35% to $1.5 billion in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $1.5 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.0 billion in Q3 2025.